Back to Search Start Over

Posttransplantation Cyclophosphamide-based Graft versus Host Disease Prophylaxis with Non-myeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis

Authors :
Tania Jain
Hua-Ling Tsai
Amy E. DeZern
Lukasz P. Gondek
Hany Elmariah
Javier Bolaños-Meade
Leonido Luznik
Ephraim Fuchs
Richard Ambinder
Douglas E. Gladstone
Philip Imus
Jonathan Webster
Gabrielle Prince
Gabriel Ghiaur
B. Douglas Smith
Syed Abbas Ali
Alexander Ambinder
William B. Dalton
Christian B. Gocke
Carol Ann Huff
Ivana Gojo
Lode Swinnen
Nina Wagner-Johnston
Ivan Borrello
Ravi Varadhan
Mark Levis
Richard J. Jones
Source :
Transplant Cell Ther
Publication Year :
2022

Abstract

We describe outcomes after post-transplantation cyclophosphamide and nonmyeloablative conditioning-based allogeneic blood or marrow transplantation for myelofibrosis using matched or mismatched related or unrelated donors. The conditioning regimen consisted of fludarabine, cyclophosphamide, and total body irradiation. Forty-two patients were included, with a median age of 63 years, of whom 19% had Dynamic International Prognostic Scoring System (DIPSS)-plus intermediate-1 risk, 60% had intermediate-2 risk, and 21% had high-risk disease, and 60% had at least 1 high-risk somatic mutation. More than 90% of patients engrafted neutrophils, at a median of 19.5 days, and 7% experienced graft failure. At 1 year and 3 years, respectively, overall survival was 65% and 60%, relapse-free survival was 65% and 31%, relapse was 5% and 40%, and nonrelapse mortality was 30% and 30%. Acute graft-versus-host disease grade 3-4 was seen in 17% of patients at 1 year, and chronic graft-versus-host disease requiring systemic therapy in occurred in 12% patients. Spleen size ≥17 cm or prior splenectomy was associated with inferior relapse-free survival (hazard ratio [HR], 3.50; 95% confidence interval [CI], 1.18 to 10.37; P = .02) and higher relapse rate (subdistribution HR [SDHR] not calculable; P = .01). Age60 years (SDHR, 0.26; 95% CI, 0.08 to 0.80, P = .02) and receipt of peripheral blood grafts (SDHR, 0.34; 95% CI, 0.11 to 0.99; P = .05) were associated with a lower risk of relapse. In our limited sample, the presence of a high-risk mutation was not statistically significantly associated with an inferior outcome, although ASXL1 was suggestive of inferior survival (SDHR, 2.36; 95% CI, 0.85 to 6.6; P = .09). Overall, this approach shows outcomes comparable those of to previously reported approaches and underscores the importance of spleen size in the evaluation of transplantation candidates.

Details

Language :
English
Database :
OpenAIRE
Journal :
Transplant Cell Ther
Accession number :
edsair.doi.dedup.....64f682f44b2cddb9b941d9a7eb4487e3